A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

UNLABELLED Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-Hodgkin's lymphoma (NHL), this phase I/II clinical trial of 67Cu-2IT-BAT-Lym-1 was conducted in an effort to further improve the therapeutic index of Lym-1-based radioimmunotherapy. Lym-1 is a mouse monoclonal antibody that preferentially targets malignant lymphocytes. 67Cu has beta emissions comparable to those of 131I but has gamma emissions more favorable for imaging. The macrocyclic chelating agent 1,4,7,11-tetraazacyclotetradecane-N,N',N",N"'-tetraacetic acid binds 67Cu tightly to form a stable radioimmunoconjugate in vivo. METHODS All 12 patients had stage III or IV NHL that had not responded to standard therapy; 11 had intermediate- or high-grade NHL. At 4-wk intervals, patients received up to four doses of 67Cu-2IT-BAT-Lym-1, 0.93 or 1.85-2.22 GBq/m2 (25 or 50-60 mCi/m2), with the lower dose used when NHL was detected in the bone marrow. RESULTS 67Cu-2IT-BAT-Lym-1 provided good imaging of NHL and favorable radiation dosimetry. The mean radiation ratios of tumor to body and tumor to marrow were 28:1 and 15:1, respectively. Tumor-to-lung, -kidney and -liver radiation dose ratios were 7.4:1, 5.3:1 and 2.6: 1, respectively. This 67Cu-2IT-BAT-Lym-1 trial for patients with chemotherapy-resistant NHL had a response rate of 58% (7/12). No significant nonhematologic toxicity was observed. Hematologic toxicity, especially thrombocytopenia, was dose limiting. CONCLUSION 67Cu remains an option for future clinical trials. This study established 67Cu-2IT-BAT-Lym-1 as a safe, effective treatment for patients with NHL.

[1]  J. L. Coffey,et al.  Calculating dose from remaining body activity: a comparison of two methods. , 1979, Medical physics.

[2]  S. Denardo,et al.  Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.

[3]  A. Epstein,et al.  Non-dehalogenation Mechanisms for Excretion of Radioiodine after Administration of Labeled Antibodies , 1988, The International journal of biological markers.

[4]  S. Martin,et al.  A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies , 1989, Hematological oncology.

[5]  E. W. Bradley,et al.  Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. , 1989, International journal of radiation oncology, biology, physics.

[6]  J. Schlom,et al.  Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. , 1990, Journal of the National Cancer Institute.

[7]  T. Fears,et al.  Non-Hodgkin's lymphoma time trends: United States and international data. , 1992, Cancer research.

[8]  M. Czuczman,et al.  Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Denardo,et al.  A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates , 1994, Cancer.

[10]  G. Denardo,et al.  Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.

[11]  R. Levy,et al.  Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G. Denardo,et al.  Antibody responses to macrocycles in lymphoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  H. Speisky,et al.  Liver copper storage and transport during development: implications for cytotoxicity. , 1996, The American journal of clinical nutrition.

[14]  G L DeNardo,et al.  Increased survival associated with radiolabeled lym‐1 therapy for non‐hodgkin's lymphoma and chronic lymphocytic leukemia , 1997, Cancer.

[15]  F. Buchegger,et al.  Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  G. Denardo,et al.  Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Lamborn,et al.  Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Glennie,et al.  Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. , 1998, Cancer research.

[19]  J. McGahan,et al.  Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Denardo,et al.  Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. , 1998, Anticancer research.

[21]  J. McGahan,et al.  Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. , 1998, Cancer biotherapy & radiopharmaceuticals.